Spinal Stenosis - Pipeline Review, H1 2014

Spinal Stenosis - Pipeline Review, H1 2014

Summary

Global Markets Direct’s, ‘Spinal Stenosis - Pipeline Review, H1 2014’, provides an overview of the Spinal Stenosis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Spinal Stenosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Spinal Stenosis and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Spinal Stenosis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Spinal Stenosis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Spinal Stenosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Spinal Stenosis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Spinal Stenosis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Spinal Stenosis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Spinal Stenosis Overview 6
Therapeutics Development 7
Pipeline Products for Spinal Stenosis - Overview 7
Pipeline Products for Spinal Stenosis - Comparative Analysis 8
Spinal Stenosis - Therapeutics under Development by Companies 9
Spinal Stenosis - Pipeline Products Glance 10
Clinical Stage Products 10
Early Stage Products 11
Spinal Stenosis - Products under Development by Companies 12
Spinal Stenosis - Companies Involved in Therapeutics Development 13
Mesoblast Limited 13
LTT Bio-Pharma Co., Ltd. 14
Sucampo Pharmaceuticals, Inc. 15
Spinal Stenosis - Therapeutics Assessment 16
Assessment by Monotherapy Products 16
Assessment by Target 17
Assessment by Mechanism of Action 19
Assessment by Route of Administration 21
Assessment by Molecule Type 23
Drug Profiles 25
SPI-017 - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
ecraprost - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
NeoFuse - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
SPI-3608 - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
LT-0101 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Spinal Stenosis - Recent Pipeline Updates 32
Spinal Stenosis - Product Development Milestones 34
Featured News & Press Releases 34
Jan 11, 2013: Mesoblast’s Neofuse Stem Cell Product Shows Positive Results In Phase II Lumbar Spinal Fusion Trial 34
Appendix 35
Methodology 35
Coverage 35
Secondary Research 35
Primary Research 35
Expert Panel Validation 35
Contact Us 36
Disclaimer 36

List of Tables
Number of Products under Development for Spinal Stenosis, H1 2014 7
Number of Products under Development for Spinal Stenosis - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Comparative Analysis by Clinical Stage Development, H1 2014 10
Comparative Analysis by Early Stage Development, H1 2014 11
Products under Development by Companies, H1 2014 12
Spinal Stenosis - Pipeline by Mesoblast Limited, H1 2014 13
Spinal Stenosis - Pipeline by LTT Bio-Pharma Co., Ltd., H1 2014 14
Spinal Stenosis - Pipeline by Sucampo Pharmaceuticals, Inc., H1 2014 15
Assessment by Monotherapy Products, H1 2014 16
Number of Products by Stage and Target, H1 2014 18
Number of Products by Stage and Mechanism of Action, H1 2014 20
Number of Products by Stage and Route of Administration, H1 2014 22
Number of Products by Stage and Molecule Type, H1 2014 24
Spinal Stenosis Therapeutics - Recent Pipeline Updates, H1 2014 32

List of Figures
Number of Products under Development for Spinal Stenosis, H1 2014 7
Number of Products under Development for Spinal Stenosis - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Comparative Analysis by Clinical Stage Development, H1 2014 10
Assessment by Monotherapy Products, H1 2014 16
Number of Products by Top 10 Target, H1 2014 17
Number of Products by Stage and Top 10 Target, H1 2014 18
Number of Products by Top 10 Mechanism of Action, H1 2014 19
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 20
Number of Products by Top 10 Route of Administration, H1 2014 21
Number of Products by Stage and Top 10 Route of Administration, H1 2014 22
Number of Products by Top 10 Molecule Type, H1 2014 23
Number of Products by Stage and Top 10 Molecule Type, H1 2014 24